New York's hometown paper is once again owned by a Chicago-based newspaper holding company, following the 'New York Daily News' sale on Monday to Tronc Inc. In a way, it's like deja vu. Tronc wasformerly Tribune Publishing, the publisher of the 'Chicago Tribune,' which originally created the 'New York Daily News' nearly a century ago.
NYS Entity Status
NYS Filing Date
MAY 08, 2013
NYS DOS ID#
NYS Entity Type
FOREIGN BUSINESS CORPORATION
2013 - LGT CAPITAL PARTNERS HOLDING (USA) INC.
Around the Web
- NY's Hometown Paper Once Again Owned By Chicago Publisher
Tuesday Sep 5, 2017
- Hannity fans smash Keurig brewers over pulled ads
By Associated Press - Monday Nov 13, 2017
A decision by Keurig to stop advertising on Sean Hannity's Fox News program has supporters of the conservative host destroying the company's coffee makers.Keurig announced Saturday that...
To view the full story, click the title link.
- Near The East River, Plans Emerge For NY’s Next Life Science Center
By Ben Fidler - Monday Aug 21, 2017
At a time when biotech incubators and shared spaces are beginning to multiply in Manhattan, work on what could rank among the city’s largest biotech centers—if it can all come together—is just getting underway. According to Paul Wexler, a longtime healthcare-focused real estate broker, construction should begin next year on what is being called the […]
- Coach Inc. is changing its name, and shoppers are pissed
By Reuters - Wednesday Oct 11, 2017
Coach Inc will change its corporate name to Tapestry Inc, it said on Wednesday, as it creates a broader umbrella for its high-end brands without diluting the iconic name known mainly for selling luxury handbags. The company’s shares were down 2 percent in early trading following the announcement in which Tapestry will be the holding...
- Food & Wine Magazine Will Leave New York for Alabama
By STEPHANIE STROM - Friday Jun 23, 2017
The move reflects a changing business in which traditional food magazines, and a Manhattan address, are less important.
- Acorda Takes Another Hit, Reports Patient Deaths in Parkinson’s Study
By Ben Fidler - Wednesday Nov 15, 2017
Acorda Therapeutics’ rebuilding plan just suffered another setback, leaving the fate of one of the experimental Parkinson’s disease drugs that is closest to market unclear. Ardsley, NY-based Acorda (NASDAQ: ACOR) said Wednesday morning that it has seen troubling safety problems in a Phase 3 trial of its experimental Parkinson’s disease drug tozadenant. Acorda reported cases […]